Summarized by Masters of Longevity from Longevity Technology.
A GLP-1–based peptide achieved histologic MASH resolution in a treated cohort.

Key Takeaways
- Zabopegdutide produced histologic resolution of MASH in 62.5% of patients.
- The 48-week outcomes were assessed by liver biopsy as the endpoint.
- Findings are from a clinical trial and are not proof of causality.



